Adlai Nortye Ltd. (NASDAQ:ANL) Short Interest Up 28.0% in December

Adlai Nortye Ltd. (NASDAQ:ANL) was the recipient of a significant increase in short interest in the month of December. As of December 15th, there was short interest totalling 3,200 shares, an increase of 28.0% from the November 30th total of 2,500 shares. Based on an average daily volume of 14,500 shares, the days-to-cover ratio is presently 0.2 days.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $9.00 price target on shares of Adlai Nortye in a research note on Monday, November 11th.

Adlai Nortye Trading Down 3.7 %

Shares of Adlai Nortye stock opened at $2.31 on Tuesday. The company has a 50-day simple moving average of $2.37 and a two-hundred day simple moving average of $2.67. Adlai Nortye has a twelve month low of $1.85 and a twelve month high of $17.48.

Adlai Nortye Company Profile

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.